ClinicalTrials.gg
Not yet recruitingNCT07796984ACTELIN 2Updated Sep 1, 2026

Study of the Intracerebral Electrophysiological Signature in the Epileptic Patient

An observational study in Epilepsy, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by University Hospital, Toulouse · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsy by University Hospital, Toulouse — 5 open to participants now, 6 under way, none of them phase 3. Epilepsy · University Hospital, Toulouse.

Started
2026
with 1 other
Observational
4 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Epilepsy by University Hospital, Toulouse, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 10th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

5 of the 10 studies in Epilepsy by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsy by University Hospital, Toulouse, or all of them as a file.
02

Study summary

As part of the clinical management of certain severe, drug-resistant forms of epilepsy, it is necessary to implant electrodes in the brain to identify the epileptic network prior to potential neurosurgical resection of the source zones. This standardized procedure, known as Stereo-Electroencephalography (SEEG), was developed in France in the 1960s. The electrodes remain implanted for several days-typically two weeks-while awaiting spontaneous epileptic seizures. During this period, the patient remains hospitalized, and their electroencephalographic activity is recorded around the clock.

Patients can be asked to perform cognitive tasks (such as tasks involving memory, attention, vision, language, and decision-making) while awake or asleep; the results can then be correlated with the intracerebral electroencephalographic activity recorded simultaneously as part of their clinical care. This approach makes it possible to capture the electrophysiological signatures of specific cognitive processes, thereby enabling researchers to: 1) create a brain map of electrophysiological signatures, 2) improve standard models of cognitive function, and 3) study the dysfunction of these processes in epilepsy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • epilepsy
  • cognitive task
  • stereoelectroencephalography
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with drug-resistant epilepsy hospitalized for stereo-electroencephalography

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with drug-resistant focal epilepsy undergoing SEEG evaluation as part of the pre-surgical workup for epilepsy
  • Intellectual capacity sufficient to perform cognitive tasks, receive information about the study procedure, and understand the information sheet

Exclusion criteria

Exclusion Criteria:

  • Patients already participating in another research project that prohibits participation in another study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Target follow-up
3 Weeks
Patient registry
Yes

Groups and cohorts

  • Patients hospitalized for SEEG with cognitive tasks

    Other: Cognitive tasks in the form of questionnaires

Interventions

  • OtherCognitive tasks in the form of questionnaires

    During their hospitalization for SEEG, patients will perform cognitive tasks to assess memory, vision, attention, language, and decision-making.

06

What researchers measure

Primary outcomes

  1. Construction of a database of electrophysiological signatures of various cognitive functions

    Correlation of performance on a task involving a neurocognitive process with characteristics of brain activity recorded during the task (electrophysiological signature) using intracranial stereo-electroencephalography (SEEG) electrodes.

    Time frame: 3 weeks after the inclusion

Secondary outcomes

  1. Evaluation of the impact of epilepsy on these electrophysiological signatures

    Significant impact of the patient's epilepsy on the normal electrophysiological signature expected during certain cognitive processes.

    Time frame: 3 weeks after the inclusion

  2. Determine whether a given brain region is dysfunctional in certain epileptic patients by comparing it with the atlas of normal physiological signatures.

    Identification of a dysfunctional brain region in an epileptic patient if the electrophysiological signature differs significantly from that expected based on the atlas.

    Time frame: 3 weeks after the inclusion

07

Study locations

1 site
  • Electrophysiologie cérébrale, épilepsie, sommeil, Hôpital Pierre Paul Riquet
    Toulouse, Oui 31000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2031, 60 months later.

Of 193 non-industry observational studies under Epilepsy, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 179. This study's planned 60 months is close to that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Sep 1, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2031
CompletionEst.
Oct 31, 2031
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07796984
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2031 (estimated)
Completion
Oct 31, 2031 (estimated)
Last update
Sep 1, 2026

Study contacts

Jonathan Curot, PHD
Contact
curot.j@chu-toulouse.fr
05 61 77 94 88 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion